ALKERMES | ALKS - Capitale Ordinario

Prezzo Delle Azioni
33.59
Cambio Giornaliero
-0.13 -0.37%
Mensile
-3.60%
Annuale
5.68%
Q2 Previsione
32.32




Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Amgen USD 540M 1000K 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
J&J USD 2.41B 1.74M 2025-12
Malin Corporation EUR 200K 0 2024-12
Merck USD 2.47B 12.72M 2025-12
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Otsuka Holdings JPY 527.31M 824K 2026-03
Ovoca Bio EUR 29.49M 18.43M 2025-06
Pfizer USD 5.69B 1000K 2025-09
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Vertex Pharmaceuticals USD 254M 0 2025-12